Early clinical outcomes as a function of use of newer oral P2Y12 inhibitors versus clopidogrel in the EUROMAX trial | Open Heart

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Archive

Authors

About

Topic collection
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Interventional cardiology

Original research article

Early clinical outcomes as a function of use of newer oral P2Y₁₂ inhibitors versus clopidogrel in the EUROMAX trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Huber K, Ducrocq G, Hamm CW, et al

Early clinical outcomes as a function of use of newer oral P2Y₁₂ inhibitors versus clopidogrel in the EUROMAX trial

Open Heart 2017;4:e000677. doi: 10.1136/openhrt-2017-000677